1 Biotech That Biogen Should Buy ... but Probably Won't

Biogen's (NASDAQ:BIIB) disclosure that aducanumab doesn't appear to help patients with Alzheimer's disease is a major blow to the big biotech's future growth, especially since its pipeline is fairly limited. The simple solution would be to use the $4.9 billion it had sitting in the bank at the end of 2018 to acquire something -- anything! -- to boost its revenue.